Biotechnology > Soligenix

Tracking since May 20, 2026 · Latest signal May 16, 2026 · 2 matched data points

Overall sentiment

Positive 100% (2)Negative 0% (0)Neutral 0% (0)

Daily sentiment

Claims (1)

Claims contributing to this aggregate. Confirmed negative claims count as negative impact; confirmed positive claims count as positive impact.

Soligenix's HyBryte treatment for cutaneous T-cell lymphoma has demonstrated safety and efficacy based on peer-reviewed clinical data.

Parent: BiotechnologyEntity: SoligenixSub-entity: HyBryteImpact: positiveDate: May 16, 2026Target: Soligenix's HyBryte treatment for cutaneous T-cell lymphoma has demonstrated safety and efficacy based on peer-reviewed clinical data.2 matched entries2 confirmed0 disputed0 neutral0 unclear